medmix AG (SWX:MEDX)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
8.50
-0.05 (-0.58%)
May 13, 2026, 5:31 PM CET
Market Cap347.75M -17.6%
Revenue (ttm)448.00M -7.4%
Net Income6.40M
EPS0.15
Shares Out40.67M
PE Ratio57.00
Forward PE16.02
Dividend0.10 (1.17%)
Ex-Dividend DateApr 20, 2026
Volume29,508
Average Volume63,859
Open8.52
Previous Close8.55
Day's Range8.50 - 8.65
52-Week Range8.10 - 13.02
Beta0.79
RSI44.70
Earnings DateJul 23, 2026

About medmix AG

medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments. The company offers dispensers, cartridges, mixers, tips, syringes, pen, and auto injectors for delivery of dental materials; delivery devices and mixing for bone repair and tissue treatment, which are used for prosthetics, restoratives, anesthetics, and aesthetics; the pen and auto injectors, which are used in fertility and growth hormone treatments, treatment of... [Read more]

Founded 1922
Employees 2,574
Stock Exchange SIX Swiss Exchange
Ticker Symbol MEDX
Full Company Profile

Financial Performance

Financial Statements

News

medmix AG Earnings Call Transcript: H2 2025

Gross profit and margins improved year-over-year despite revenue declines, driven by cost savings and strong dental performance. Guidance for 2026 is cautious, with flat to low single-digit organic growth and margin stability, as dual sourcing and tariffs remain headwinds.

2 months ago - Transcripts

medmix AG Earnings Call Transcript: H1 2025

Gross profit and profitability improved above guidance despite lower revenues, driven by cost savings and efficiency gains. Dental and Surgery segments outperformed, while Beauty and Industry faced headwinds. Full-year revenue is expected to decline, but margin guidance is maintained.

10 months ago - Transcripts

medmix AG Earnings Call Transcript: H2 2024

Gross profit and cash flow improved in 2024 despite lower revenues, with strong dental and surgery growth offset by declines in drug delivery and industry. A CHF 30 million cost-saving program is underway, with flat revenues and EBITDA margin of 18%-19% expected for 2025.

1 year ago - Transcripts

medmix AG Earnings Call Transcript: H1 2024

Revenue declined year-over-year but improved sequentially, with gross margin gains and strong cash flow recovery driven by dental and industry segments and the Qiaoyi acquisition. Full-year guidance was revised down due to soft end market demand, but management remains optimistic about long-term growth, especially in healthcare.

1 year ago - Transcripts